Porcilis PCV M Hyo


porcine circovirus type 2 ORF2 subunit antigen / Mycoplasma hyopneumoniae inactivated

This medicine is authorised for use in the European Union.


An overview of Porcilis PCV M Hyo and why it is authorised in the EU

Porcilis PCV M Hyo is a veterinary vaccine used to protect pigs against two separate infections, caused by porcine circovirus and Mycoplasma hyopneumoniae.

  • Porcine circovirus type 2 (PCV2) infections can produce clinical signs such as weight loss or failure to grow, enlarged lymph nodes, difficulty in breathing, diarrhoea, pale skin and jaundice (yellowing of the skin).
  • Infection with the bacterium Mycoplasma hyopneumoniae in pigs causes a disease of the airways called enzootic pneumonia. Affected pigs often have a cough and fail to thrive.

Porcilis PCV M Hyo contains porcine circovirus type 2 (PCV2) subunit antigen (a protein derived from part of the virus) and an inactivated (killed) strain of Mycoplasma hyopneumoniae bacteria.

This EPAR was last updated on 18/06/2020

Authorisation details

Product details
Porcilis PCV M Hyo
Agency product number
Active substance
Porcine circovirus type 2 (PCV2) ORF2 subunit antigen, Mycoplasma hyopneumoniae J strain inactivated
International non-proprietary name (INN) or common name
  • porcine circovirus type 2 ORF2 subunit antigen
  • Mycoplasma hyopneumoniae inactivated
Pigs (for fattening)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

15/06/2020 Porcilis PCV M Hyo - EMEA/V/C/003796 - IA/0014

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for suidae

  • Inactivated viral and inactivated bacterial vaccines

Therapeutic indication

For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (PCV2) infection, and severity of lung lesions caused by Mycoplasma hyopneumoniae infection. To reduce the loss of daily weight gain during the finishing period in face of infections with Mycoplasma hyopneumoniae and/or PCV2 (as observed in field studies)

Assessment history


How useful was this page?

Add your rating
1 rating
1 rating